

UCI 16-19 ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy (Uchio)

UCI 18-13** A Randomized Phase III, Open-Label Trial of Sipuleucel-T Administered to Patients on Active Surveillance for Newly Diagnosed Prostate Cancer (Uchio)

***SUSPENDED* UCI 16-76** Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365) (Mar)


UCI 17-25** A Phase 2, Open-Label, 2-Arm, Response Rate Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer Who Previously Received Taxane-Based Chemotherapy and Progressed on at Least 1 Novel Hormonal Agent (Enzalutamide and/or Abiraterone Acetate/ Prednisone) (Uchio)

UCI 17-41** A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients with Prostate Cancer and Cardiovascular Disease Receiving Degarelix (GnRH Receptor Antagonist) or Leuprolide (GnRH Receptor Agonist) (Uchio)

UCI 17-86 Phase 1 Trial of Efficacy and Feasibility of Robot Assisted Salvage Pelvic Lymph Node Dissection (RS-PLND) or Robot Assisted Salvage Pelvic Mass Resection (RS-PMR) Post-Robot Assisted Radical Prostatectomy (Ahlering)

UCI 18-47* A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Talazoparib with Background Enzalutamide in Metastatic Castration-Resistant Prostate Cancer with DNA Damage Repair Deficiencies (TALAPRO-2) (Uchio)

Non-Metastatic



Metastatic

Both


UCI 17-48 HERO: A Multinational Phase 3 Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of Relugolix in Men with Advanced Prostate Cancer (Uchio)

**Opening soon

For more details contact
1-877-UC-STUDY or ucstudy@uci.edu


UCI 17-40 Precision Medicine for Early Prostate Cancer: Integrating Biological and Patient Complexity Variables to Predict Treatment Response (Uchio)

UCI 18-36** Long-Term Prospective Registry to Evaluate Treatment Decisions and Clinical Outcomes in Patients with Favorable Intermediate-Risk Localized Prostate Cancer Following Cell Cycle Progression (CCP) Testing (Polaris® Test) (Uchio)




**Opening soon

For more details contact
1-877-UC-STUDY or ucstudy@uci.edu



****Opening soon**



****Opening soon**


For more details contact
1-877-UC-STUDY or ucstudy@uci.edu

Prostate/Renal

UCI 16-01 Pathway Analyses for Individualized Network Therapeutics for Cancer (PAINT Cancer) (Nelson)

Prostate/Bladder

UCI 17-90 A Two-Part Phase I, Open Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Pyrotinib in Patients with HER2-Positive Solid Tumors Whose Disease Progressed on Prior HER2 Targeted Therapy (Ou)



Renal

UCI 07-40 Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, a C-MET/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer (Ou)

All

ECOG EAY131 Molecular Analysis for Therapy Choice (MATCH) (Bota)

SWOG S1609 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (Bota)

- 17: Epithelial tumors of penis - squamous adenocarcinoma cell carcinoma with variants of penis
- 18: Squamous cell carcinoma variants of the genitourinary (GU) system
- 19: Spindle cell carcinoma of kidney, pelvis, ureter

UCI 16-96 A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (Ou)

UCI 17-50 A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors (Ou)

UCI 18-19** An Open-Label, Phase Ib Multicenter Study of IBI308 in Subjects with Advanced/Metastatic Solid Malignancies (Ou)

UCI 18-14** A Phase I, Open-Label, Multicenter Dose Escalation Study of RMC-4630 Monotherapy in Adult Patients with Relapsed/Refractory Solid Tumors (Ou)

**Opening soon

For more details contact
1-877-UC-STUDY or ucstudy@uci.edu